Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2026-10-20
Target enrollment:
Participant gender:
Summary
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety,
and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive
B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline
immunochemotherapy.